Figure 1.

Effect of peptide K5 on the production of inflammatory mediators. (a), (b), (c), and (d) Levels of NO, PGE₂, and TNF-α were determined by Griess assay, EIA, and ELISA from culture supernatants of RAW264.7 cells or peritoneal macrophages treated with peptide K5 (0 to 100 μg/mL) and LPS (1 μg/mL) for 6 (TNF-α) or 24 (NO and PGE₂) h. (e) Phagocytic uptake levels of FITC-dextran were determined by flow cytometric analysis using RAW264.7 cells treated with peptide K5 (0 to 100 μg/mL) and FITC-dextran (1 μg/mL) for 6 (TNF-α) or 24 (NO and PGE₂) h. (e) Cell viability of RAW264.7 cells and peritoneal macrophages was determined by MTT assay. *P < 0.05 and **P < 0.01 compared to control.